
    
      This trial is designed to assess the pharmacokinetics, safety and tolerability of
      brexpiprazole in the treatment of subjects with schizophrenia. The trial will consist of two
      parts across 13-36 months. The trial population will include approximately 110 male & female
      subjects between 18 and 64 years of age (inclusive) with a diagnosis of schizophrenia as
      defined by DSM-V criteria.
    
  